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Abstract
Background and Objectives: In North America, preoperative combination chemor-
adiation is the most commonly recommended and utilized approach to locally
advanced rectal cancer. There is increasing interest in the use of induction
chemotherapy (IC) before radiation and surgery in locally advanced rectal cancer.
How widely IC is being used and whether it improves pathologic and oncologic
outcomes is unknown.
Methods: We evaluated clinical stage 2 or 3 rectal cancer patients in the National
Cancer Database between 2006 and 2015. We identified predictors of use of IC with
multivariable logistic regression and compared survival between groups using Cox
proportional hazards regression.
Results: Among 36 268 patients, IC use increased significantly over time from 5.5% in
2006 to 15.9% in 2015 (P < 0.001). Treatment at a hospital with a high IC rate was an
independent predictor of receipt of IC. IC and traditional therapy yielded similar
pathologic complete response rates (32.2% vs 30.5%, P = 0.2) and similar 5‐year
survival (82.4% vs 81.4%, 0.71).
Conclusions: Use of IC for locally advanced rectal cancer has increased significantly.
The choice of IC seems to be driven more by institutional and regional practice
patterns than clinical characteristics and is not associated with improved pathologic
or oncologic outcomes.
K E YWORD S
induction chemotherapy, rectal neoplasm, survival
1 | INTRODUCTION
Optimal management of locally advanced rectal involves multi-
modality therapy including chemotherapy, radiation, and surgery.
Since the publication of the German Rectal Cancer Trial,1,2 the
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most commonly recommended practices have changed from
postoperative combination chemoradiation to preoperative com-
bination chemoradiation and adjuvant systemic chemotherapy.
Adherence to neoadjuvant chemoradiotherapy remains inade-
quate; however, with significant variation in treatment based on
center type, volume, and geographic location.3 More recently,
single‐center studies have reported the use of induction
chemotherapy (IC) before combination chemotherapy and radia-
tion followed by surgery,4,5 with the goals of introducing systemic
therapy earlier in the course of treatment, and potentially
increasing the rate of complete pathologic response.6 Others
have endorsed the delivery of all chemotherapy and radiation
before surgery, recognizing that surgical complications preclude
adjuvant chemotherapy in up to 34% of patients.7,8 There is only
a small phase 2 randomized trial comparing IC to adjuvant
chemotherapy, which did not identify a difference in pathologic
complete response or survival between groups.9 Despite this, the
National Comprehensive Cancer Network Guidelines now include
IC among endorsed options for treatment of stages 2 and 3 rectal
cancer.10
To date, large scale or randomized studies comparing IC against
standard preoperative chemoradiation are lacking. The National
Cancer Institute‐supported PROSPECT trial randomized patients to
standard chemoradiation or IC with the selective omission of
preoperative radiation, but outcomes of this trial are still forth-
coming.11 On the one hand, IC might induce the more preoperative
response, reducing the likelihood of local failure, and treating occult
metastatic disease earlier. On the other hand, delayed surgery might
allow local expansion and worsen the likelihood of surgical margin
clearance and leave more time for the primary tumor to metastasize.
The real‐world outcomes of the IC strategy cannot be assessed
without population‐based evaluation outside of highly‐selected case
series. The prevalence of IC use outside of the highly specialized
institutions that have reported its use is unknown.
In this study, we used the National Cancer Database (NCDB),
which includes data from all American College of Surgeons
Commission on Cancer accredited hospitals, accounting for approxi-
mately 70% of all cancer patients in treated US hospitals.12 This
population‐based cohort offers a realistic epidemiologic assessment
of the outcomes of patients with locally advanced rectal cancer
nationwide. We used data on timing of chemotherapy, radiation and
surgery to classify therapy as either IC before radiation or traditional
concurrent chemoradiation before surgery. We sought to understand
time trends and patient and provider characteristics associated with
the use of IC, and the clinical and pathologic outcomes of IC
compared with traditional chemoradiation.
2 | MATERIALS AND METHODS
2.1 | Patient selection
We queried the NCDB Participant Use File from 2006 to 2015 and
identified all patients with clinical stage 2 or 3 rectal cancer. The
analysis was limited to patients who underwent preoperative
chemoradiation and surgery for invasive adenocarcinoma, mucinous
adenocarcinoma, or signet ring cell carcinoma of the rectum with
curative intent.
Among patients who received radiation and/or chemotherapy as
initial course of therapy, we defined two groups of interest using
variables available in the NCDB (1) the IC group was defined as
patients who received chemotherapy separate from radiation before
surgery and (2) traditional therapy was defined as patients who
received concurrent chemotherapy and radiation before surgery
(Figure 1). The NCDB records patients as having received
chemotherapy if they receive any type at any time, and characterizes
chemotherapy as either preoperative or postoperative. It does not
distinguish chemotherapy regimens and thus cannot differentiate
5‐FU with leucovorin and oxaliplatin (FOLFOX), for example, from
single agent 5‐fluorouracil (5‐FU) or capecitabine. Thus, to identify
patients who received IC separately from radiation, we used the
timing of initiation of chemotherapy compared with the timing of
initiation of radiation therapy. Examination of the interval between
initiation of chemotherapy and radiation revealed a clear transition
point at the 10‐day mark, whereby patients who appeared to have
received combined chemoradiation were generally clustered around
a fewer than 10‐day difference, distinct from a group that had start
times much greater than 10 days. IC patients were thus defined as
stage 2 or 3 patients who received both preoperative chemotherapy
and radiation, but with start dates greater than 10 days apart. The
traditional therapy patients were defined as those who started
F IGURE 1 Definitions of induction chemotherapy (IC) and traditional therapy groups of stages 2 and 3 rectal cancer patients
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chemotherapy and radiation concurrently less than 10 days apart—in
fact, a majority of these patients started both on the same day. To
further specify the comparison group of traditional chemoradiother-
apy followed by surgery, we excluded patients who underwent
surgery greater than 22 weeks after chemotherapy and radiation, as
these likely represent patients who initially refused surgery, had
substantial complications of therapy, or initially pursued nonopera-
tive management.
2.2 | Statistical analysis
Descriptive statistics were used to compare characteristics of
patients between treatment groups, using χ2 tests for categorical
variables, the Student t test for continuous variables, and analysis of
variance for multicategory comparisons of continuous data. We
identified independent predictors of receiving IC using multivariable
logistic regression, including patient factors (age, race, rectal cancer
stage, place of residence, income, type of insurance, and receipt of
postoperative chemotherapy) and hospital factors (regional location
and facility type) that were significant in the univariate analysis. We
categorized the hospital rate of IC into quartiles and included this in
the model to account for the role of institutional practice patterns.
We compared overall survival between therapy regimens using
multivariable Cox proportional hazard regression, adjusting for the
same patient and hospital factors as above, and applying robust
standard errors to account for clustering of outcomes within
hospitals. All statistical analyses were conducted using STATA
version 14 (StataCorp LP, College Station, TX).
3 | RESULTS
3.1 | Patient and hospital characteristics
Of 36 268 patients included in the analysis, 3241 (8.9%) received IC.
The proportion of patients receiving IC increased significantly over
time (Figure 2), from 5.5% in 2006 to 15.9% in 2015 (P < 0.001). The
annual rate of increase was greatest between 2011 and 2014.
3.2 | Predictors of receipt of IC
Comparisons of patient characteristics in IC and traditional therapy
groups are shown in Table 1. Patients who received IC were slightly
younger (58.6 vs 59.7, P < 0.001), and more likely to be non‐white
(24.8% vs 18.5%, P < 0.001), have Medicaid (8.1% vs 6.8%, P < 0.001),
residing in a zip code in the top or bottom income bracket (53.4% vs
47.4%, P < 0.001) and lowest education bracket (19.3% vs 15.9%,
P < 0.001), and residing in a metropolitan area (83.3% vs 78.1%,
P < 0.001). IC was also more common among those with clinical stage
3 disease (59.6% vs 53.6%, P < 0.001).
Univariable comparisons of hospital characteristics treating
rectal cancer patients in the IC or traditional therapy groups is
shown in Table 2. Patients receiving IC were more likely to be
treated in an Academic/Research Program Hospital (42.4% vs 32.8%,
P < 0.001) and more likely to be treated in the Middle Atlantic region
(18.6% vs 12.7%, P < 0.001).
In multivariable logistic regression analysis, displayed in Table 3,
patient characteristics that were independently associated with
receipt of IC included: Black (odds ratio [OR], 1.18; 95% confidence
interval [CI],1.02‐1.36) or Hispanic (OR, 1.20; CI, 1.01‐1.41) race,
being from a rural area (OR, 1.36; CI, 1.04‐1.79), and having stage 3
cancer (OR, 1.21; CI, 1.11‐1.31). Hospital characteristics indepen-
dently associated with receipt of IC included location in the Middle
Atlantic region (OR, 1.25; CI, 1.02‐1.54) and being treated in a
hospital with a higher proportional use of IC (OR, 22.4; CI, 17.97‐
27.92 for highest vs lowest quartile). The change in the relationship
to receipt of IC between the univariate and multivariable analysis for
rural patients appears to be because the vast majority of these
patients (67%) receive treatment at hospitals that have low
utilization of IC.
3.3 | Clinical and pathologic outcomes, by
treatment group
The proportion of patients who had complete tumor regression on
pathology was not different between the IC and traditional groups
(32.2% vs 30.4%, P = 0.20). Likewise, the unadjusted survival
functions between the two treatment groups were not significantly
different (P = 0.85). Graphical display of the Cox regression survival
analysis, adjusting for patient and hospital factors, is shown in
Figure 3. Adjusting for patient and hospital characteristics, the IC
group had equivalent survival to the traditional care group. Five‐year
survival for traditional therapy was 81.4%, while for IC, it was
82.4%, (P = 0.71).
4 | DISCUSSION
In this study, we find that, despite the lack of large randomized trials
to support IC, there has been a steady annual increase in its use for
clinical stages 2 and 3 rectal cancer and that the primary determinant
of this use is institutional practice pattern, rather than clinical
F IGURE 2 The percentage of patients receiving induction
chemotherapy (IC) increased over time [Color figure can be viewed
at wileyonlinelibrary.com]
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indications. Patients who were Black or Hispanic, from a rural area,
had stage 3 cancer, or were treated at a hospital in the Middle
Atlantic region were also more likely to receive IC. We did not find;
however, evidence to support an effect of IC on the likelihood of
either complete pathologic response or overall survival. This study
utilized data from the NCDB, which is a population‐based, nation-
wide sample, representing the vast majority of treated rectal cancers
in US hospitals. Thus, it provides a realistic assessment of national
practice patterns beyond just specialty referral centers.
The use of IC is just one of several recent changes in the
prevailing treatment approaches for rectal cancer. In general, the
trend has been toward more treatment being given before
TABLE 1 Patient characteristics of stage 2 and 3 rectal cancer
who received traditional therapy or induction chemotherapy (IC)
Patient characteristics
Traditional
(N = 33 012) IC (N = 3241) P value
Mean age (SD), n (%) 59.7 (12.2) 58.6 (12.3) <0.001
<50 years old 7676 (23.3) 836 (25.8)
50‐60 years old 9694 (29.4) 978 (30.2)
60‐70 years old 8949 (27.1) 863 (26.6)
70 + years old 6693 (20.3) 564 (17.4)
Female 12 386 (37.5) 1216 (37.5) 1.0
Race/ethnicity, n (%) <0.001
White 28 754 (87.1) 2717 (83.8)
Black 2487 (7.5) 324 (10.0)
Asian 1323 (4.0) 143 (4.4)
Other 448 (1.4) 57 (1.8)
Hispanic 1777 (5.6) 269 (8.6)
Insurance, n (%) <0.001
Private insurance 17 113 (51.8) 1713 (52.9)
Medicare 11 248 (34.1) 991 (30.6)
Medicaid 2248 (6.8) 263 (8.1)
Other government
insurance
488 (1.5) 43 (1.3)
Not insured 1509 (4.6) 189 (5.8)
Income quartiles, n (%)a <0.001
<38K 5593(17.0) 595 (18.5)
38K‐48K 8244 (25.1) 680 (21.2)
48K‐63K 9017 (27.5) 819 (25.5)
>63K 9963 (30.4) 1120 (34.9)
Education, n (%)a,b <0.001
≥29% (lowest edu) 5098 (15.9) 602 (19.3)
20%‐28.9% 7.738 (24.2) 733 (23.4)
14%‐19.9% 7979 (25.0) 714 (22.8)
<14% (highest edu) 11 165 (34.7) 1079 (34.5)
Urban/rural patient
location, n (%)
<0.001
Metropolitan 25 173 (78.1) 2595 (83.3)
Urban/Suburban 6166 (19.1) 443 (14.2)
Rural 911 (2.8) 76 (2.4)
Average distance
travelled to hospital
(SD), miles
31.5 (104.7) 30.3 (102.4) 0.56
Rectal cancer clinical
stage
<0.001
Stage 2 15 305 (46.4%) 1311 (40.5%) <0.0001
T3 13 342 1076
T4a 559 64
T4b 453 78
Stage 3 17 707 (53.6%) 1930 (59.6%) <0.001
T1/2N1 2791 146
T1N2a 19 4
T1/2N2b 20 5
T2/3N2a 1966 226
T3/4aN1 10 499 1299
T4aN2a 178 26
T3/4aN2b 277 43
T4bN1/2 603 105
Charlson/Deyo score,
n (%)
0.35
0 26 314 (79.7) 2588 (79.9)
1 5383 (16.3) 516 (15.9)
2 1001 (3.0) 96 (3.0)
3 314 (1.0) 41 (1.3)
Stage 4 on pathology 434 (2.6) 52 (3.1) 0.18
Receipt of 11 513 (34.9) 941 (29.0) <0.001
(Continues)
TABLE 1 (Continued)
Patient characteristics
Traditional
(N = 33 012) IC (N = 3241) P value
postoperative
chemotherapy
Path stage 2/3 6415 512
Path stage 4 167 18
Complete regression on
pathology, n (%)
3698 (30.4) 370 (32.2) 0.2
aAssigned by zipcode of patient’s residence.
bProportion of population without high school degree.
TABLE 2 Characteristics of hospitals treating stage 2 and 3 rectal
cancer who received traditional therapy or induction chemother-
apy (IC)
Hospital characteristics
Patients receiving treatment
in hospital type/location
Hospital type Traditional, n (%) IC, n (%) <0.001
Community Cancer
Program
2831 (9.0) 216 (7.1)
Comprehensive
Community Cancer
Program
13 985 (44.5) 1165
(38.4)
Academic/Research
Program
10 929 (34.8) 1,287
(42.4)
Integrate Network
Cancer Program
3674 (11.7) 369 (12.2)
Hospital region <0.001
New England 1775 (5.7) 206 (6.8)
Middle Atlantic 4000 (12.7) 564 (18.6)
South Atlantic 6811 (21.7) 639 (21.0)
East North Central 6462 (20.6) 547 (18.0)
East South Central 1914 (6.1) 222 (7.3)
West North Central 3342 (10.6) 181 (6.0)
West South Central 2338 (7.4) 255 (8.4)
Mountain 1508 (4.8) 110 (3.6)
Pacific 3269 (10.4) 313 (10.3)
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surgery, with increasing interest in strategies that might obviate
the need for surgery altogether for some patients. Improved
surgical technique, with total mesorectal excision and negative
circumferential margin, along with radiation, became the stan-
dard of care after studies showed a decreased risk of local
recurrence.13-16 The German rectal cancer trial established that
preoperative radiation was superior to postoperative treatment,
less from improved survival than because of decreased toxicity.2
Thus, some have pursued IC to avoid failures to receive
chemotherapy after surgery due to perioperative complications.8
In addition, Habr‐Gama showed that preoperative multimodal
treatment resulted in tumor shrinkage and thus improved
sphincter preservation, suggesting a role for IC in reducing the
rate of permanent colostomy.17 In another study, some patients
who achieved an apparent complete clinical response to pre-
operative therapy did well over time without surgery.18 Since
that time, multiple studies aimed to improve local tumor response
through increasing multimodal preoperative therapy, though
randomized, multi‐institution data in support of such approaches
is still lacking.4,5,19
Because there has not been a large randomized trial of the use
of IC in rectal cancer, currently available studies must be
interpreted with caution. In 2010 Chua et al20 reported on 105
patients who received 12 weeks of IC with oxaliplatin and
capecitabine followed by 54 Gy of radiation over 6 weeks, then
surgery, then another 12 weeks of chemotherapy and showed
that this was feasible. An additional feasibility study moving all of
the planned chemotherapy to before radiation was reported in
2014 from Memorial Sloan‐Kettering treating 57 patients with
induction FOLFOX.4 This group more recently published a
retrospective comparison of their single‐institution data compar-
ing 320 patients receiving chemotherapy and radiation followedT
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F IGURE 3 Survival analysis comparing induction chemotherapy
and traditional care. Cox proportional hazard regression analysis
revealed equivalent survival between patients receiving induction
chemotherapy separate from radiation (IC) and those receiving
traditional therapy [Color figure can be viewed at
wileyonlinelibrary.com]
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by surgery and then chemotherapy to 308 patients receiving all
of their therapy before surgery.5 The only randomized trial was a
phase 2 study from Spain which compared IC to adjuvant in a
total of 108 patients and this study did not identify a difference
in pathologic complete response (the primary endpoint) or
survival between groups despite improved compliance with
receipt of planned chemotherapy.9,21
In summary, the use of IC may achieve one of two goals. First,
sensitive tumors will shrink completely before surgery and
patients will receive earlier systemic therapy. The second is that
many but not all patients receive a survival benefit from
FOLFOX22 and tumors with a greater period of time in situ will
have a theoretical increased potential for metastasis before
resection of the primary tumor. Two recent studies of rectal
cancer patients with pathologic complete response using the
NCDB found that these patients did have a survival benefit from
adjuvant chemotherapy.23,24 However, we do not yet know how
to predict who these patients are and these are clearly the
sensitive tumors so it follows logically that these patients would
benefit. Only long‐term data from a well‐designed trial that
includes detailed tumor information will help us to understand
whether we are helping patients or allowing more time for
metastasis by changing our treatment algorithm.
There are limitations to the current study. First, because in
NCDB data, it is not possible to ascertain exact chemotherapy
regimens, we do not know exactly what the patients received.
Nevertheless, we applied careful, clinically reasoned assignment
to treatment groups, according to criteria that distinguish
patients most likely to have received systemic chemotherapy
separate from radiation. Second, NCDB does not contain other
endpoints such as local and distant recurrence rates which would
be of interest. Third, because this was an observational study,
there may be selection bias in the assignment of patients to IC vs
standard chemoradiation that could affect the pathologic and
oncologic outcome comparisons. However, recognizing that the
most powerful predictor of use of IC was the institutional
practice pattern, rather than patient characteristics, confounding
by indication was likely less influential, as treatment decisions
seem to have more to do with the provider than patient
differences. Further, because the clinical and pathologic out-
comes were nearly identical, even in this national data set, it is
unlikely that clinically important confounding has altered the
conclusions.
In conclusion, the use of IC for patients with locally advanced
rectal cancer in NCDB is increasing over time, but it is still used in
only a minority of patients in the US. Overall, the strongest
predictor of treatment algorithm including IC was the treating
institution's rate of use of IC, indicating that patients are
receiving different treatments at different hospitals, driven
primarily by local practice patterns. We found no association
between the use of IC and improved overall survival or rate of
pathologic complete response. Thus, prospective data are needed
to better establish the role of IC in the management of locally
advanced rectal cancer.
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